Yesterday, AtheroNova Inc. (AHRO-OTC) announced a major milestone in the Company's progression to Phase I clinical trials. AtheroNova has now shipped Phase I supplies of AHRO-001, the Company's lead drug candidate fighting atherosclerotic plaque, to CardioNova, the Company's Russian licensing partner. This shipment was the last major step to commencing human trials, and indicates that AtheroNova is on track to start patient screenings and first-in-man dosing in June 2013.

"We are very excited to partner with a great organization like Crystal Research. With fewer sell-side firms capable and willing to provide research coverage for small and microcap stocks, we see tremendous value in independent research. After seeing Jeff and his team work with a few of our clients, we were extremely impressed with their diligent process and comprehensive reports. Forming this partnership allows us to leverage our collective strengths to help investors fully understand our client's stories and to increase investor and media awareness and interest in our client's companies."

This morning we released our first Executive Informational Overview on Trio Resources, Inc. (TRII-OTC), a Canadian mineral exploration company that is also active in mineral processing. The report details Trio's business, exploration efforts, mineralized assets and process for monetizing these assets, important partnerships, management background, growth strategies, potential competition, and market opportunities, among many other factors that investors and stakeholders may find relevant.

Continuing with our "earnings season highlights" coverage, LRAD Corp. (LRAD-NASDAQ) has reported its fiscal second quarter 2013 financials, which entail results for the Company’s three- and six-month period ended March 31, 2013.  

In addition to the below discussion, detailed information from Crystal Research Associates about LRAD’s business, product lines, strategies, market opportunities, and competition is available here, and the Company’s SEC filings can be accessed here.   

Our second post on "earnings season highlights" focuses on technology company Neonode Inc.(NEON-NASDAQ), which last week reported quarterly financials for the three months ended March 31, 2013. (For the first in this blog series—coverage of PhotoMedex, Inc.’s first quarter earnings—click here.)  

In addition to the below discussion, detailed information from Crystal Research Associates about Neonode’s business, product lines, strategies, market opportunities, and competition is available here, and the Company’s SEC filings can be accessed here.